In this podcast, IMF Chairman of the Board Dr. Brian G.M. Durie interviews myeloma patient Leo Dierckman, who is now MRD negative. Leo was brave enough to enter into the ASCENT clinical trial, an aggressive treatment trial for the management of high-risk smoldering myeloma sponsored by the IMF Black Swan Research Initiative.® Leo has done incredibly well. After completing two full years of treatment (induction and consolidation, followed by maintenance), he has now been off all therapy for over a year and is — three years since the start of treatment — MRD negative. His story of hope and optimism for a potential myeloma cure is not to be missed!